InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the stock.

Separately, Lake Street Capital started coverage on shares of InspireMD in a research note on Wednesday, December 11th. They issued a “buy” rating and a $5.00 price target for the company.

InspireMD Trading Down 5.6 %

Shares of NSPR stock opened at $2.55 on Wednesday. The company has a market cap of $66.50 million, a PE ratio of -3.40 and a beta of 0.99. The company’s fifty day simple moving average is $2.84 and its 200-day simple moving average is $2.73. InspireMD has a 52 week low of $1.81 and a 52 week high of $3.42.

InspireMD (NYSE:NSPR) last posted its earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. The business had revenue of $1.81 million for the quarter, compared to analysts’ expectations of $1.74 million. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. During the same period in the previous year, the company posted ($0.15) earnings per share. Equities research analysts expect that InspireMD will post -0.79 EPS for the current fiscal year.

Institutional Investors Weigh In On InspireMD

An institutional investor recently raised its position in InspireMD stock. Affiance Financial LLC grew its holdings in shares of InspireMD, Inc. (NYSE:NSPR) by 2.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 189,122 shares of the company’s stock after buying an additional 5,376 shares during the period. Affiance Financial LLC owned 0.73% of InspireMD worth $497,000 as of its most recent filing with the Securities and Exchange Commission. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.